NeuroOne Medical Technologies Corp

NeuroOne Medical Technologies Corp. is a medical technology company, which engages in the development and commercialization of thin film electrode technology for continuous electroencephalogram and stereoelectrocencephalography recording, spinal cord stimulation, brain stimulation, and ablation solutions. The company was founded by Mark Christianson on August 20, 2009 and is headquartered in Eden Prairie, MN.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EDEN PRAIRIE, Minn., Dec. 15, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; "NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today financial results for the quarter and full fiscal year ended September 30, 2021.

NeuroOne Reports Fourth Fiscal Quarter and Full Fiscal Year 2021 Financial Results and Provides Corporate Update

EDEN PRAIRIE, Minn., Dec. 6, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today it will host a conference call to discuss financial results for its fourth quarter and fiscal year ended September 30, 2021, on December 15, 2021, at 9:00 AM Eastern Time.

NeuroOne to Host Fourth Quarter 2021 Earnings Call

NeuroOne is a developer of flexible, minimally invasive, thin film electrodes for cEEG and sEEG recording, and the diagnosis and treatment of neurological conditions. Mayo Clinic is a key development partner and shareholder, and Zimmer Biomet is a strategic development and marketing partner.

NeuroOne: Thin Film Electrodes For Diagnosis And Treatment Of Neurological Conditions

EDEN PRAIRIE, Minn., Oct. 13, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the pricing of an underwritten registered public offering of 3,750,000 shares of its common stock at a price of $3.20 per share.

NeuroOne Medical Technologies Corporation Announces Pricing of Public Offering of Common Stock

EDEN PRAIRIE, Minn., Oct. 12, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has commenced a proposed underwritten registered public offering of shares of its common stock.

NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock

EDEN PRAIRIE, Minn., Sept. 23, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it successfully completed an animal feasibility study of its combination recording and ablation technology at T3 Labs and Georgia State/Georgia Tech Center for Advanced Brain Imaging in Atlanta Georgia under the guidance of Dr. Robert Gross of Emory University.

NeuroOne® Medical Technologies Corporation Announces Successful Completion of Feasibility Study for Ablation Electrode

EDEN PRAIRIE, Minn., Sept. 9, 2021 /PRNewswire/ -- NeuroOne ®  Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today that management will present at the H.C.

NeuroOne to Present at H.C. Wainwright 23rd Annual Global Investment Conference

EDEN PRAIRIE, Minn., Sept. 7, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Evo sEEG Electrode technology for temporary (less than 24 hours) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.

NeuroOne® Medical Technologies Corporation Receives FDA 510(k) Clearance for its Evo® sEEG Electrode

EDEN PRAIRIE, Minn., Aug. 25, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, was featured on Cheddar News, in a segment titled, "Can This Brain Implant Save Lives?

NeuroOne Featured on Cheddar News (VIDEO): "Can This Brain Implant Save Lives?"

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has executed an agreement with RBC Medical Innovations for a proprietary radiofrequency (RF) generator. The program will develop and manufacture an RF generator for use with NeuroOne's ablation electrode designed to record brain activity and ablate brain tissue using the same electrode.

NeuroOne, RBC Medical Innovations Come Together For Ablation Device Program

EDEN PRAIRIE, Minn., Aug. 23, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; "NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today that it has executed an agreement with RBC Medical Innovations to develop and manufacture a proprietary radiofrequency (RF) generator for use with NeuroOne's combination recording and ablation electrode that is being designed to both record brain activity and ablate brain tissue using the same electrode.

NeuroOne Announces Strategic Partnership with RBC Medical Innovations for Ablation Program

NeuroOne Medical Technologies' (NMTC) CEO Dave Rosa on Q3 2021 Results - Earnings Call Transcript

EDEN PRAIRIE, Minn., Aug. 13, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; "NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today financial results for the quarter ended June 30, 2021.

NeuroOne Reports Third Quarter Fiscal 2021 Financial Results and Corporate Update

EDEN PRAIRIE, Minn. , Aug. 11, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today it will host a conference call to discuss financial results for its third quarter ended June 30, 2021, on August 13, 2021, at 9:00 AM ET.

NeuroOne to Host Third Quarter 2021 Earnings Call

EDEN PRAIRIE, Minn., July 28, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today that the Company will participate in Alliance Global Partners (A.G.P.

NeuroOne to Participate in Alliance Global Partners (A.G.P.) Virtual MedTech Summer Conference on July 29, 2021

EDEN PRAIRIE, Minn., July 7, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC; NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today that the company will present at Access to Giving Virtual Conference.

NeuroOne to Present at Access to Giving Virtual Conference on July 15, 2021 at 2 p.m. ET

EDEN PRAIRIE, Minn., June 2, 2021 /PRNewswire/ --  NeuroOne Medical Technologies Corporation  (NASDAQ: NMTC; NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today the formation of a six member advisory board of leading neurosurgeons to assist in the completion of development of a radio frequency ablation electrode intended to record and ablate brain tissue linked to causing seizure activity.

NeuroOne Introduces Advisory Board for Ablation Electrode Technology that Records and Ablates Brain Tissue Linked to Seizure Activity

EDEN PRAIRIE, Minn., May 25, 2021 /PRNewswire/ --  NeuroOne Medical Technologies Corporation  (OTCQB: NMTC; NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today it has been approved to uplist to The Nasdaq Capital Market.

News for NeuroOne Medical Technologies Corp Stock (NMTC)